WO2020004202A1 - COMPOSITION CONTENANT DU D-chiro-INOSITOL - Google Patents

COMPOSITION CONTENANT DU D-chiro-INOSITOL Download PDF

Info

Publication number
WO2020004202A1
WO2020004202A1 PCT/JP2019/024383 JP2019024383W WO2020004202A1 WO 2020004202 A1 WO2020004202 A1 WO 2020004202A1 JP 2019024383 W JP2019024383 W JP 2019024383W WO 2020004202 A1 WO2020004202 A1 WO 2020004202A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
inositol
chiro
salt
Prior art date
Application number
PCT/JP2019/024383
Other languages
English (en)
Japanese (ja)
Inventor
信哉 宅見
公輔 田中
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Publication of WO2020004202A1 publication Critical patent/WO2020004202A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition comprising D-chiro-inositol.
  • the present invention also relates to an external preparation containing the composition.
  • Inositol (1,2,3,4,5,6-cyclohexanehexaol) has a structure in which one hydrogen atom on each carbon of cyclohexane is replaced by one hydroxy group, and is known as a vitamin-like active substance. I have. Inositol has nine types of stereoisomers depending on the combination of hydroxy group configurations.
  • Patent Document 1 discloses a hair restorer containing inositol as an active ingredient.
  • “inositol” used in the prior art refers to myo-inositol (cis-1,2,3,5-trans-4) as an additive for pharmaceuticals, quasi-drugs, cosmetics, and the like. , 6-cyclohexanehexaol) (see, for example, Non-Patent Documents 1 to 3).
  • the present inventors have found that among stereoisomers of inositol, chiro-inositol is a compound useful as a hair restorer (see Patent Document 2).
  • D-chiro-inositol is a water-soluble compound among the isomers of inositol.
  • D-chiro-inositol was found to be an inositol stereoisomer as well as in aqueous solution. It has been found that a precipitate tends to be formed.
  • D-chiro-inositol has a very low solubility in solvents other than water, and tends to form precipitates more easily when an aqueous solution having a water ratio of less than a predetermined value is placed in a low-temperature environment. It is in.
  • an object of the present invention is to provide a composition capable of suppressing the precipitation of D-chiro-inositol.
  • the present inventors have conducted intensive studies in order to solve the above-mentioned problems.
  • the composition containing D-chiro-inositol has a D-chiro-inositol content of D-chiro-inositol equal to or higher than a predetermined value.
  • the present inventors have found that the composition is capable of suppressing the deposition of chiro-inositol, and have completed the present invention.
  • the present invention provides the following inventions.
  • [6] including a salt of an organic acid
  • the surfactant comprises a nonionic surfactant.
  • the nonionic surfactant comprises polyoxyethylene hydrogenated castor oil or polyoxyethylene polyoxypropylene alkyl ether.
  • An external preparation containing the composition according to any one of [1] to [10].
  • An external preparation for scalp comprising the composition according to any one of [1] to [10].
  • composition capable of suppressing the precipitation of D-chiro-inositol even in a low-temperature environment.
  • composition of the present invention is a composition containing D-chiro-inositol and water.
  • D-chiro-inositol examples include, but are not particularly limited to, those extracted from naturally occurring buckwheat, beans, citrus, etc., those extracted and purified from legumes by fermentation, those chemically synthesized, and Commercial products can be mentioned.
  • the extraction method is not particularly limited, and a known extraction method can be used.
  • the content of D-chiro-inositol in the composition of the present invention is not particularly limited, but is preferably 0.001 to 20% by mass, more preferably 0.01 to 20% by mass, and still more preferably 0 to 20% by mass. 0.05 to 15% by mass, more preferably 1 to 10% by mass, still more preferably 3 to 7% by mass.
  • % by mass means the mass percentage of the components contained in the composition with respect to the mass of the entire composition.
  • X to Y means that it is X or more and Y or less.
  • the composition of the present invention can be used as an external preparation.
  • external preparations include, for example, agents for cracks and irrigations, agents for rashes and sores, agents for sea urchin and octopus, agents for dryness and irritations, agents for wrinkles and spots, humectants, hair dyes, hair restorers, shampoos, Rinse, conditioner, lotion, cream, milky lotion, hand cream, medicated soap, pack and the like can be mentioned.
  • the composition of the present invention contains D-chiro-inositol, a composition having a vitamin-like effect and a hair-growth activity can be obtained, and may be used as a hair-growth agent.
  • the hair growth activity is, specifically, an activity relating to hair shaft growth promotion, hair growth, prevention of hair loss, and the like, and preferably an activity relating to hair shaft growth promotion and hair growth.
  • the composition of the present invention may further include an organic acid or a salt thereof.
  • the composition of the present invention preferably contains an organic acid and a salt of the organic acid.
  • the feeling of use in a preparation containing the composition of the present invention can be improved. It tends to be. It is presumed that such an effect is attributable to the fact that the organic acid or a salt thereof exerts a chelating effect and functions to reduce the stimulus contributed by a solvent other than water, for example, a monoalcohol having 1 to 3 carbon atoms. (However, the factor is not limited to this.)
  • the organic acid means an organic compound which is acidic alone in water.
  • the organic acid is not particularly limited as long as it is an organic compound exhibiting acidity, and examples thereof include monocarboxylic acids and polycarboxylic acids, and organic sulfonic acids.
  • monocarboxylic acids and organic sulfonic acids are preferable, and organic sulfonic acids are more preferable, from the viewpoint of suppressing the precipitation of D-chiro-inositol.
  • the monocarboxylic acid means an organic compound having one carboxylic acid in the molecule
  • the polyvalent carboxylic acid means an organic compound having two or more carboxylic acids in the molecule
  • the organic sulfonic acid means an organic compound having at least one sulfonic acid in a molecule.
  • a monocarboxylic acid For example, Formic acid, acetic acid, propionic acid, and valeric acid are mentioned.
  • polyvalent carboxylic acid examples include, but are not particularly limited to, dicarboxylic acid, tricarboxylic acid, and tetracarboxylic acid, and include, for example, citric acid, edetic acid, phthalic acid, isophthalic acid, terephthalic acid, succinic acid, fumaric acid, and maleic acid. Acids, malic acid, and tartaric acid. Among these, citric acid and edetic acid are preferred.
  • Organic sulfonic acids include, but are not limited to, methanesulfonic acid, benzenesulfonic acid, and taurine.
  • the salt in the organic acid salt is not particularly limited, and includes, for example, a sodium salt, a potassium salt, a calcium salt, and a magnesium salt. Of these, sodium salts are preferred.
  • the organic acids or salts thereof may be used alone or in combination of two or more. When two or more kinds are used in combination, a combination of two or more kinds of organic acids or a combination of two or more kinds of salts of organic acids may be used. These may be used in combination. When an organic acid and a salt of the organic acid are used, the organic acid and the organic acid of the salt of the organic acid may be the same or different, but the organic acid and the salt of the organic acid are used in combination. Is preferred.
  • the content of the organic acid or a salt thereof in the composition of the present invention is not particularly limited, but is usually 0.001 to 5% by mass, preferably 0.01 to 3% by mass, more preferably 0.03% by mass. To 1% by mass, more preferably 0.05 to 1% by mass.
  • the composition of the present invention may further include a surfactant.
  • a surfactant By containing a surfactant, it tends to be possible to suppress the precipitation of D-chiro-inositol in an aqueous solution containing D-chiro-inositol.
  • a surfactant in the composition of the present invention, it tends to be possible to improve the feeling of use in a preparation containing the composition of the present invention. It is presumed that the factor that exerts such effects is due to the fact that the surfactant improves the solubility of D-chiro-inositol in an aqueous solution (however, the factor is not limited to this).
  • the surfactant examples include, but are not particularly limited to, a nonionic surfactant, a cationic surfactant, an anionic surfactant, and an amphoteric surfactant.
  • nonionic surfactants are preferable from the viewpoint that a good feeling in use is obtained, particularly, from the viewpoint of excellent permeability into pores.
  • One type of surfactant may be used alone, or two or more types may be used in combination.
  • the HLB value of the surfactant is not particularly limited, but is preferably 2 to 17, more preferably 6 to 17, and even more preferably 12 to 17.
  • HLB is an abbreviation for hydrophile-lipophile balance, and is one of the indices indicating the effect of a surfactant.
  • the HLB value when two or more surfactants are contained is a weighted average of the HLB values of each surfactant.
  • the nonionic surfactant means a surfactant that does not exhibit ionicity in an aqueous solution.
  • Nonionic surfactants include, but are not particularly limited to, for example, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene sorbitan oleate, monoesters of oleic acid and glycerin, and oleic acid. Esters of diglycerin.
  • polyoxyethylene-hardened castor oil and polyoxyethylene poly-polyethylene are preferred from the viewpoint of suppressing the precipitation of D-chiro-inositol and obtaining a good feeling in use, particularly from the viewpoint of excellent permeability into pores.
  • Oxypropylene alkyl ethers are preferred.
  • the cationic surfactant and the anionic surfactant mean a surfactant that becomes a cation and an anion when dissociated in an aqueous solution, respectively, and the amphoteric surfactant has a pH of the aqueous solution in the aqueous solution.
  • Means a surfactant that becomes one of a cation, an anion, and a zwitterion depending on the Examples of the cationic surfactant include, but are not particularly limited to, alkyldimethylamine, alkyltrimethylammonium salt, and dialkyldimethylammonium salt.
  • the anionic surfactant include, but are not particularly limited to, fatty acid salts and alkyl sulfates.
  • Examples of the amphoteric surfactant include, but are not particularly limited to, alkylamino fatty acid salts, alkyl betaines, and alkylamine oxides.
  • the content of the surfactant in the composition of the present invention is not particularly limited, but is usually 0.1 to 10% by mass, preferably 0.5 to 7% by mass, and more preferably 1 to 5% by mass. It is.
  • the content of water in the composition of the present invention is not particularly limited as long as it contains water within a range of 40% by mass or more, but is preferably 70% by mass or less, more preferably 50% by mass or less.
  • the proportion of water is within the above range, it becomes possible to suppress the precipitation of D-chiro-inositol even in a low-temperature environment, particularly when the composition of the present invention contains an organic acid or a salt thereof.
  • This also makes it possible to suppress the precipitation of D-chiro-inositol.
  • a factor that exerts such an effect is that D-chiro-inositol is precipitated in a low-temperature environment because the water content is 40% by mass or more because D-chiro-inositol is water-soluble.
  • the organic acid or its salt functions to reduce the promotion of D-chiro-inositol precipitation by exerting a chelating action (however, the factor is not limited to this).
  • the factor is not limited to this.
  • water examples include pure water such as ion-exchanged water, ultrafiltration water, reverse osmosis water, and distilled water, and water from which ionic impurities such as ultrapure water have been removed as much as possible.
  • the composition of the present invention may further contain a mono- and / or polyhydric alcohol having 1 to 3 carbon atoms.
  • a polyhydric alcohol By containing a polyhydric alcohol, it tends to be possible to suppress the precipitation of D-chiro-inositol in an aqueous solution containing D-chiro-inositol.
  • a monoalcohol having 1 to 3 carbon atoms and / or a polyhydric alcohol By containing a monoalcohol having 1 to 3 carbon atoms and / or a polyhydric alcohol, a composition having antibacterial properties and moisture retention tends to be obtained.
  • the monoalcohol having 1 to 3 carbon atoms is methanol, ethanol, n-propanol and isopropanol, preferably ethanol and isopropanol, and more preferably ethanol.
  • the polyhydric alcohol means an alcohol having two or more hydroxyl groups in a molecule.
  • glycerin ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol (1,2-propanediol), dipropylene glycol, trimethylolpropane, 1,3-propylene glycol ( 1,3-propanediol), isobutylene glycol (2-methyl-1,2-propanediol), 1,2-butanediol, 1,3-butyleneglycol (1,3-butanediol), 1,4-butane Diol, 2-butene-1,4-diol, 1,2-pentanediol, 1,5-pentanediol, 2-methyl-2,4-pentanediol, 1,2-hexanediol, 1,6-hexanediol , 2-ethyl-1,3-hexanediol, 1, - heptanediol
  • the content of the mono-alcohol having 1 to 3 carbon atoms in the composition of the present invention is not particularly limited, but the content of the mono-alcohol having 1 to 3 carbon atoms can be set high.
  • the content of the monoalcohol having 1 to 3 carbon atoms in the composition of the present invention is usually 80% by mass or less, may be 60% by mass or less, may be 30 to 60% by mass, and may be 30 to 50% by mass. Or 30 to 40% by mass.
  • the content of the polyhydric alcohol in the composition of the present invention is not particularly limited, but is usually 0.1% by mass or more, preferably 0.5% by mass or more, more preferably 0.5 to 30% by mass. And more preferably 0.5 to 20% by mass, and still more preferably 0.5 to 15% by mass.
  • the composition of the present invention may further include a monoterpene.
  • a monoterpene By containing a monoterpene, there is a tendency that a refreshing feeling can be imparted and a composition excellent in suppressing the precipitation of D-chiro-inositol can be obtained.
  • monoterpene examples include, but are not particularly limited to, monoterpene hydrocarbons such as limonene, pinene, and camphor; monoterpene alcohols such as citronellol, geraniol, linalool, menthol, terpineol, and borneol; monoterpenes such as citronellal, citral, and safranal Aldehydes; monoterpene ketones such as menthone, carbomentone, and yonone; Preferably, it is a monoterpene alcohol, and more preferably, menthol. These monoterpenes may be d-, l-, or dl-form.
  • menthol for example, l-menthol and d-menthol are preferred, and l-menthol is more preferred. It may be used as a mixture of 1-menthol and d-menthol. Monoterpenes may be used alone or in combination of two or more.
  • the content of the monoterpene in the composition of the present invention is not particularly limited, but in addition to imparting a refreshing feeling, suppressing precipitation of D-chiro-inositol, suppressing dripping and irritating feeling (crisp feeling) of the obtained composition. And 0.01 to 10% by mass, more preferably 0.05 to 2% by mass, and still more preferably 0.1 to 1.0% by mass because of excellent suppression of separation of the monoterpene itself. %, And still more preferably 0.7 to 1.0% by mass.
  • composition of the present invention may further contain additives that are generally acceptable in pharmaceuticals, quasi-drugs, cosmetics, and the like.
  • additives include, but are not limited to, excipients, stabilizers, odor correctors, bases, dispersants, diluents, emulsifiers, transdermal absorption enhancers, preservatives, coloring agents, oils (oils, fats, minerals, Oil, etc.), thickeners, polymers, film-forming agents, ultraviolet absorbers, cell activators, antioxidants, preservatives, fresheners, deodorants, pigments, dyes, fragrances, sugars, amino acids, vitamins, Organic acids, organic amines, plant extracts and the like can be mentioned.
  • the composition of the present invention is not particularly limited, and can be produced by mixing components contained in the present invention.
  • the order of mixing the components is not particularly limited.
  • the conditions for mixing are not particularly limited, and the composition of the present invention can be obtained according to a conventionally known method.
  • the composition of the present invention when used as an external preparation, it can be used as a drug, a quasi-drug, a cosmetic or the like.
  • it can be used as an external preparation for skin, an external preparation for hair, and an external preparation for scalp, and more specifically, a dermatological drug, a hair drug and a scalp drug, a quasi-drug for skin, and a hair
  • It can be used for quasi-drugs and quasi-drugs, as well as skin cosmetics, hair cosmetics and scalp cosmetics. More specifically, it can be in the form of an ointment, cataplasm, liniment, lotion, topical solution, dusting agent, cream, gel, emulsion, hair tonic, hair spray.
  • the “external preparation for hair” and the “external preparation for scalp” may be the same or different in the form and usage as the external preparation. Or scalp.
  • “external preparation for skin” is a concept including “external preparation for scalp” and means an external preparation that acts directly on the skin without being limited to the scalp.
  • the method of the invention comprises the step of administering a composition of the invention to a subject.
  • the dose of D-chiro-inositol per administration to a subject is not particularly limited, but is preferably 0.005 to 200 mg, more preferably 0.05 to 100 mg, and still more preferably 0.5 to 100 mg. 10 mg.
  • the frequency of administration of the composition of the present invention to a subject is not particularly limited, but is preferably 1 to 6 times per day, more preferably 1 to 3 times per day, and still more preferably 1 to 3 times per day. ⁇ 2 times.
  • composition of the present invention is administered is not particularly limited, and includes, for example, humans, animals such as domestic animals and pets.
  • D-chiro-inositol D-chiro-inositol (manufactured by Wako Pure Chemical Industries, Ltd .; hereinafter abbreviated as "DCI”) [Organic acid or salt thereof] Citric acid (Showa Kako) Sodium citrate (Showa Kako Co., Ltd .; hereinafter abbreviated as "Na citrate”) Sodium edetate (manufactured by Junsei Chemical Co., Ltd .; hereinafter, abbreviated as “Na edetate”) [Surfactant] HCO-10 (polyoxyethylene (10) hydrogenated castor oil, HLB value: 6.5, manufactured by Nikko Chemicals) HCO-20 (polyoxyethylene (20) hydrogenated castor oil, HLB value: 10.5, manufactured by Nikko Chemicals) HCO-40 (polyoxyethylene (40) hydrogenated castor oil, HLB value: 12.5, manufactured by Nikko Chemicals) H
  • Example 1 A solution obtained by dissolving DCI and an organic acid and / or a salt thereof in purified water and adding a solution obtained by mixing EtOH and a surfactant so that each component has the composition shown in Table 1 below is added. Each composition was diluted and mixed to prepare a formulation.
  • Formulation stability test The obtained preparation was evaluated for the precipitation of DCI in each composition by the following method. Formulations of each composition were prepared in 3 lots, and DCI precipitation was induced by a low-temperature cycle (12 hours 5 ° C incubation, 12 hours -20 ° C repeated for 14 days), and visually evaluated based on the following indices did. The evaluation results are shown in Table 1 (the number of N is 3). In all lots, no precipitation of crystals was observed " ⁇ " Even with 1Lot, slight precipitation of crystalline material was observed " ⁇ " Even with 1 Lot, a small number of crystals were precipitated. Even with 1 Lot, many crystals precipitated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

L'invention a pour objectif d'obtenir une composition permettant d'empêcher la précipitation du D-chiro-inositol. Plus spécifiquement, l'invention concerne une composition contenant: du D-chiro-inositol et de l'eau, la teneur en eau étant inférieure à 40% en poids.
PCT/JP2019/024383 2018-06-29 2019-06-19 COMPOSITION CONTENANT DU D-chiro-INOSITOL WO2020004202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-125198 2018-06-29
JP2018125198A JP2020002107A (ja) 2018-06-29 2018-06-29 Ｄ−ｃｈｉｒｏ−イノシトールを含む組成物

Publications (1)

Publication Number Publication Date
WO2020004202A1 true WO2020004202A1 (fr) 2020-01-02

Family

ID=68986233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/024383 WO2020004202A1 (fr) 2018-06-29 2019-06-19 COMPOSITION CONTENANT DU D-chiro-INOSITOL

Country Status (2)

Country Link
JP (1) JP2020002107A (fr)
WO (1) WO2020004202A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7478452B2 (ja) 2020-01-09 2024-05-07 国立大学法人東京農工大学 光検出装置、光検出方法
WO2023228911A1 (fr) * 2022-05-26 2023-11-30 一丸ファルコス株式会社 Nouvel agent pour améliorer la résilience et/ou le corps des cheveux

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006028026A (ja) * 2004-07-12 2006-02-02 Doctor Program Kk 育毛剤
JP2008169185A (ja) * 2007-01-15 2008-07-24 Hoyu Co Ltd 毛髪処理剤組成物及び毛髪処理方法
JP2009108023A (ja) * 2007-10-11 2009-05-21 Rohto Pharmaceut Co Ltd 育毛剤
WO2017188393A1 (fr) * 2016-04-27 2017-11-02 小林製薬株式会社 Agent de croissance capillaire
JP2019085339A (ja) * 2017-11-01 2019-06-06 小林製薬株式会社 Ｄ−ｃｈｉｒｏ−イノシトールを含む組成物
JP2019085342A (ja) * 2017-11-01 2019-06-06 小林製薬株式会社 Ｄ−ｃｈｉｒｏ−イノシトールを含む組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006028026A (ja) * 2004-07-12 2006-02-02 Doctor Program Kk 育毛剤
JP2008169185A (ja) * 2007-01-15 2008-07-24 Hoyu Co Ltd 毛髪処理剤組成物及び毛髪処理方法
JP2009108023A (ja) * 2007-10-11 2009-05-21 Rohto Pharmaceut Co Ltd 育毛剤
WO2017188393A1 (fr) * 2016-04-27 2017-11-02 小林製薬株式会社 Agent de croissance capillaire
JP2019085339A (ja) * 2017-11-01 2019-06-06 小林製薬株式会社 Ｄ−ｃｈｉｒｏ−イノシトールを含む組成物
JP2019085342A (ja) * 2017-11-01 2019-06-06 小林製薬株式会社 Ｄ−ｃｈｉｒｏ−イノシトールを含む組成物

Also Published As

Publication number Publication date
JP2020002107A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
US9701924B2 (en) Ethanol-free microemulsion perfuming compositions
JP7450324B2 (ja) Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
JP7295809B2 (ja) アスコルビン酸及び／又はその塩を含有する外用組成物
EP2316412B1 (fr) Concentrés aqueux d'une grande clarté de 4-hexylrésorcinol
CN105640791A (zh) 抗微生物组合物
CN105902402A (zh) 活性混合物
JP7127978B2 (ja) Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
KR101687599B1 (ko) 보습력이 우수한 저자극성의 세정용 화장료 조성물
US9468597B1 (en) Stabilized L-ascorbic acid skin serum
CN111297745A (zh) 一种促进吸收的美白组合物及其生产工艺和应用
WO2020004202A1 (fr) COMPOSITION CONTENANT DU D-chiro-INOSITOL
CN117320685A (zh) 用于皮肤保护的包含抗微生物剂和(生物)-链烷二醇的组合物
JP2019014765A (ja) 抗菌性組成物およびその製造方法
KR20190001136A (ko) 올리고 펩타이드를 함유하는 피부개선용 리프팅 팩 조성물
WO2020004200A1 (fr) COMPOSITION CONTENANT DU D-chiro-INOSITOL
WO2020004201A1 (fr) COMPOSITION CONTENANT DU D-chiro-INOSITOL
JP7203521B2 (ja) Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
JP7328957B2 (ja) アスコルビン酸及び／又はその塩を含有する外用組成物
JP7127979B2 (ja) Ｄ－ｃｈｉｒｏ－イノシトールを含む組成物
JP5019093B2 (ja) 抗菌組成物
JP2014015422A (ja) 化粧料組成物
JP4044988B2 (ja) 化粧料
JP2024083777A (ja) 組成物
FR3139006A1 (fr) Composition de soin des matières kératineuses et masque la contenant
JP2009190986A (ja) 透明ジェル化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19826269

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19826269

Country of ref document: EP

Kind code of ref document: A1